journal article·2025-10-10

Mn3O4 Nanozymes Regulate Inflammatory Microenvironment and Restore Intestinal Barrier Function for Treating Inflammatory Bowel Disease

Ying Zhang, Jingjing Lan, Shujing Deng, Shiyan Guo, Jianfeng Xing, Kai Dong, Cuiyu You

ACS Applied Nano Materials· Volume 8· Issue 40
Publisher page

Abstract

An imbalance between excessive reactive oxygen species (ROS) production and impaired endogenous ROS scavenging capacity is central to the pathogenesis of inflammatory bowel disease (IBD). Inspired by the treatment principle of “Quxie Fuzheng” in traditional Chinese medicine, ultrasmall Mn 3 O 4 nanozymes (PEG-Mn 3 O 4 ) were prepared in this study to treat experimental colitis, which functioned through direct ROS scavenging and upregulation of superoxide dismutase 2 (SOD2) activity. In vitro experiments showed that PEG-Mn 3 O 4 exhibitedexcellent ROS scavenging activities and could release manganese ions in the inflammatory microenvironment to enhance cellular SOD2 activity, thus inhibiting oxidative stress-induced apoptosis of intestinal epithelial cells and promoting the migration of intestinal epithelial cells; and they could inhibit the expression of pro-inflammatory factors secreted by M1 macrophages. PEG-Mn 3 O 4 effectively attenuated intestinal inflammation and restored the mucosal barrier in experimental colitis by suppressing epithelial cell apoptosis and enhancing tight junction protein expression, demonstrating significant therapeutic efficacy. In addition, PEG-Mn 3 O 4 had good biocompatibility. This study utilized the multienzyme activity of PEG-Mn 3 O 4 to directly scavenge ROS to “Quxie”, and utilized its release of Mn ions to enhance the activity of cellular SOD2 in the inflammatory microenvironment to “Fuzheng”, for the treatment of colitis. The ROS-scavenging and SOD2 activity-enhancing properties of PEG-Mn 3 O 4 offer the possibility to treat other oxidative stress-related diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy

The First Affiliated Hospital of Xi’an Jiaotong University

Department of Pharmaceutics, School of Pharmacy

Xi’an Jiaotong University

Funding

National Natural Science Foundation of China · Science and Technology Development of Shaanxi Province

References (54)

Show source-provided references
1. 10.1016/S0140-6736(17)32448-010.1016/S0140-6736(17)32448-0 ↗
2. 10.1016/S0140-6736(23)00966-210.1016/S0140-6736(23)00966-2 ↗
3. 10.1016/j.tips.2024.08.00310.1016/j.tips.2024.08.003 ↗
4. 10.1001/jama.2023.1538910.1001/jama.2023.15389 ↗
5. 10.1016/j.addr.2013.10.00110.1016/j.addr.2013.10.001 ↗
6. 10.1016/j.gastre.2020.11.00910.1016/j.gastre.2020.11.009 ↗
7. 10.1056/NEJMra200269710.1056/NEJMra2002697 ↗
8. 10.1016/j.mayocp.2018.09.01310.1016/j.mayocp.2018.09.013 ↗
9. 10.3389/fimmu.2021.70397210.3389/fimmu.2021.703972 ↗
10. 10.1089/dna.2018.434810.1089/dna.2018.4348 ↗
11. 10.1038/s41563-019-0462-910.1038/s41563-019-0462-9 ↗
12. 10.1038/s41580-019-0173-810.1038/s41580-019-0173-8 ↗
13. 10.1038/s41580-019-0173-810.1038/s41580-019-0173-8 ↗
14. 10.1038/s41575-018-0021-x10.1038/s41575-018-0021-x ↗
15. 10.1016/j.cellsig.2020.10973710.1016/j.cellsig.2020.109737 ↗
16. 10.1186/1741-7015-11-17810.1186/1741-7015-11-178 ↗
17. 10.1258/ebm.2011.01135810.1258/ebm.2011.011358 ↗
18. 10.1021/jacs.7b0060110.1021/jacs.7b00601 ↗
19. 10.1002/anie.20180446610.1002/anie.201804466 ↗
20. 10.1126/sciadv.abb269510.1126/sciadv.abb2695 ↗
21. 10.1039/c8cs00457a10.1039/c8cs00457a ↗
22. 10.1021/acsnano.4c1794210.1021/acsnano.4c17942 ↗
23. 10.1002/anie.20201633010.1002/anie.202016330 ↗
24. 10.1002/adma.20221081910.1002/adma.202210819 ↗
25. 10.1002/adfm.20200469210.1002/adfm.202004692 ↗
26. 10.7150/thno.3372710.7150/thno.33727 ↗
27. 10.1021/jacs.5b1207010.1021/jacs.5b12070 ↗
28. 10.1039/C7SC05476A10.1039/C7SC05476A ↗
29. 10.1002/anie.20170857310.1002/anie.201708573 ↗
30. 10.1021/jacs.0c0380510.1021/jacs.0c03805 ↗
31. 10.1039/C6TB02078J10.1039/C6TB02078J ↗
32. 10.1021/ar200333610.1021/ar2003336 ↗
33. 10.4061/2011/38717610.4061/2011/387176 ↗
34. 10.3390/metabo1304057310.3390/metabo13040573 ↗
35. 10.1021/cm900431b10.1021/cm900431b ↗
36. 10.1097/SGA.000000000000031410.1097/SGA.0000000000000314 ↗
37. 10.1053/j.gastro.2007.11.00410.1053/j.gastro.2007.11.004 ↗
38. 10.1002/0471142735.im1525s10410.1002/0471142735.im1525s104 ↗
39. 10.1038/nrgastro.2015.18610.1038/nrgastro.2015.186 ↗
40. 10.1002/adtp.20210008110.1002/adtp.202100081 ↗
41. 10.1126/science.289.5484.156710.1126/science.289.5484.1567 ↗
42. 10.1152/physrev.00010.201410.1152/physrev.00010.2014 ↗
43. 10.1016/S0140-6736(96)90013-610.1016/S0140-6736(96)90013-6 ↗
44. 10.1021/acsnano.8b0654210.1021/acsnano.8b06542 ↗
45. 10.1016/j.jconrel.2018.08.02110.1016/j.jconrel.2018.08.021 ↗
46. 10.1021/acs.nanolett.0c0109810.1021/acs.nanolett.0c01098 ↗
47. 10.1089/ars.2011.399910.1089/ars.2011.3999 ↗
48. 10.1161/CIRCRESAHA.117.31093310.1161/CIRCRESAHA.117.310933 ↗
49. 10.1016/j.redox.2019.10120110.1016/j.redox.2019.101201 ↗
50. 10.1016/j.freeradbiomed.2006.01.03410.1016/j.freeradbiomed.2006.01.034 ↗
51. 10.1016/j.jconrel.2022.05.02510.1016/j.jconrel.2022.05.025 ↗
52. 10.1016/0016-5085(84)90202-610.1016/0016-5085(84)90202-6 ↗
53. 10.1016/j.apsb.2020.07.01910.1016/j.apsb.2020.07.019 ↗
54. 10.1155/2018/719264610.1155/2018/7192646 ↗